Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Key Inclusion Criteria: * Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment * Participants will satisfy the criteria for mild (Cohort 1) and moderate hepatic impairment (Cohort 3) defined as a Child-Pugh total score of 5 to 6 and 7 to 9 points, respectively at the screening visit * Participants will have chronic (greater than or equal to (≥) 6 months) documented liver disease * Cohorts 2 and 4: Matched Healthy Participants * Participants will be matched (cohort 2 matched to cohort 1; and cohort 4 matched to cohort 3) during screening to participants with hepatic impairment for age, sex, and weight Key Exclusion Criteria: * Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment * History of febrile illness or other acute illness that has not fully resolved by 14 days before the first dose of study drug * Severe portal hypertension * History or presence of severe hepatic encephalopathy (Grade \>2) * Any condition possibly affecting drug absorption * Significant renal dysfunction (creatinine clearance \<60 milliliter per minute \[mL/min\] ) estimated according to the method of Cockcroft and Gault at the screening Visit or Day-1 * History of solid organ or bone marrow transplantation * Cohorts 2 and 4: Matched Healthy Participants * History of febrile illness or other acute illness that has not fully resolved by 14 days before the first dose of study drug * Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply.